O sistema de expressão em Escherichia coli foi o primeiro a ser utilizado para produzir produtos farmacêuticos recombinantes e tem muitas vantagens quando comparado com sistemas eucarióticos, como o fácil cultivo, baixo custo e alto potencial de produção. O fator estimulador de colônias de granulócito (G-CSF) atua principalmente promovendo a maturação dos neutrófilos e estimulando sua atividade fagocítica e quimiotática, além de estar envolvido com o processo de segmentação nuclear dessas células. O fator estimulador de colônias de granulócitos humano recombinante (rhG-CSF) tem sido produzido por engenharia genética em Escherichia coli, e é usado no tratamento de diversas patologias, sobretudo em neutropenias provocadas pela quimioterapia usada no tratamento de tumores, pela radioterapia e pelo uso de drogas que suprimem a produção de células mieloides. Desse modo, o presente estudo teve como objetivo a expressão da proteína rhGCSF em bactérias Escherichia coli. A clonagem do gene rhG-CSF no vetor de expressão pET-28a(+) foi realizada nos sítios de restrição das enzimas EcoRI e XhoI, e a expressão da proteína recombinante em cepas de bactéria Escherichia coli BL21DE3 foi obtida com sucesso. A proteína rhG-CSF, fundida à cauda de seis histidinas, foi purificada com êxito e identificada pelas técnicas de Western Blotting e por espectrometria de massas. São necessários estudos para avaliar a integridade estrutural e atividade biológica da proteína produzida, que se confirmada, possibilita que esta seja produzida em escala piloto. / The expression system in Escherichia coli was the first to be used to produce recombinant pharmaceuticals and has many advantages compared to eukaryotic systems, such as easy cultivation and high production potential at low costs. The granulocyte colony (G-CSF) stimulating factor acts primarily by promoting the maturation of neutrophils and stimulating their phagocytic and chemotactic activity. G-CSF is also involved with the process of neutrophils nuclear segmentation. The recombinant human granulocyte colonies stimulating factor (rhG-CSF) has been produced by genetic engineering in Escherichia coli, and it is used to treat of several conditions, especially neutropenia caused by chemotherapy used in the treatment of tumors, by radiotherapy and by the use of drugs that suppress the production of myeloid cells. The present study aimed the expression of rhG-CSF protein in Escherichia coli bacteria. The cloning of rhG-CSF gene in the expression vector pET- 28a (+) was carried out on the restriction sites of the EcoRI and XhoI enzymes. Expression of the recombinant protein in Escherichia coli BL21DE3 was successfully achieved. The rhG-CSF protein, fused with a six histidine tag, was obtained and successfully purified and identified by the Western Blotting and by mass spectrometry techniques. Studies are needed to assess the structural integrity and biological activity of the protein produced, which, if confirmed, enables the production on a pilot scale.

Fundamental questions related to the locations of Cerebrospinal Spinal Fluid (CSF) absorption deficit and causes of the pressure gradients that expand the ventricles with hydrocephalus remain largely unanswered. Work in the Johnston lab over a 15 year period has demonstrated that CSF moves through the cribriform plate foramina in association with the olfactory nerves and is absorbed by a network of lymphatic vessels located within the olfactory turbinates. A kaolin-based rat model of communicating hydrocephalus was developed as a collaborative effort with Drs. McAllister, Wagshul and Li. After developing a method to quantify lymphatic CSF uptake in rats, we examined and observed that the movement of a radioactive tracer into the nasal turbinates was significantly reduced in the kaolin-injected animals compared to saline injected controls. However, it was possible that while lymphatic CSF uptake was compromised, other CSF absorption pathways may have compensated. To answer this, we measured the CSF outflow resistance (Rout) and observed it to be significantly greater in the kaolin group compared with animals receiving saline and there was a significant positive correlation between CSF Rout and ventricular volume. Nonetheless, it is not clear how impaired CSF clearance could lead to a dilation of the ventricles since the ventricular and subarachnoid compartments are in communication with one another and pressure would likely increase equally in both. At this point, we came across a theoretical paper that postulated that a drop in periventricular interstitial fluid pressure might provide an intraparenchymal pressure gradient favouring ventricular expansion. In addition, studies in non-CNS tissues indicated that a disruption of beta-1 (β1) integrin-matrix interactions could lower tissue pressure. Based on these suppositions and data, we examined if these concepts had relevance to the brain. For this, we measured pressure in the brain and observed a decline in periventricular pressures to values significantly below those monitored in the ventricular system following the injection of the anti integrin antibodies. Many of the animals developed hydrocephalus over 2 weeks post antibody injection. These data provide a novel mechanism for the generation of intraparenchymal pressure gradients that is likely contributing to ventricular expansion.

Fundamental questions related to the locations of Cerebrospinal Spinal Fluid (CSF) absorption deficit and causes of the pressure gradients that expand the ventricles with hydrocephalus remain largely unanswered. Work in the Johnston lab over a 15 year period has demonstrated that CSF moves through the cribriform plate foramina in association with the olfactory nerves and is absorbed by a network of lymphatic vessels located within the olfactory turbinates. A kaolin-based rat model of communicating hydrocephalus was developed as a collaborative effort with Drs. McAllister, Wagshul and Li. After developing a method to quantify lymphatic CSF uptake in rats, we examined and observed that the movement of a radioactive tracer into the nasal turbinates was significantly reduced in the kaolin-injected animals compared to saline injected controls. However, it was possible that while lymphatic CSF uptake was compromised, other CSF absorption pathways may have compensated. To answer this, we measured the CSF outflow resistance (Rout) and observed it to be significantly greater in the kaolin group compared with animals receiving saline and there was a significant positive correlation between CSF Rout and ventricular volume. Nonetheless, it is not clear how impaired CSF clearance could lead to a dilation of the ventricles since the ventricular and subarachnoid compartments are in communication with one another and pressure would likely increase equally in both. At this point, we came across a theoretical paper that postulated that a drop in periventricular interstitial fluid pressure might provide an intraparenchymal pressure gradient favouring ventricular expansion. In addition, studies in non-CNS tissues indicated that a disruption of beta-1 (β1) integrin-matrix interactions could lower tissue pressure. Based on these suppositions and data, we examined if these concepts had relevance to the brain. For this, we measured pressure in the brain and observed a decline in periventricular pressures to values significantly below those monitored in the ventricular system following the injection of the anti integrin antibodies. Many of the animals developed hydrocephalus over 2 weeks post antibody injection. These data provide a novel mechanism for the generation of intraparenchymal pressure gradients that is likely contributing to ventricular expansion.

Les neutrophiles sont d'une grande importance dans la première ligne de défense de l'organisme contre les pathogènes. Ils participent activement par leurs actions antimicrobiennes, comme la phagocytose et la relâche de granules, mais influencent également la réponse immunitaire par les différentes cytokines et chimiokines qu'ils produisent. L'étude des différentes fonctions du neutrophile a permis d'établir les étapes clés de la signalisation intracellulaire qui mène à ces différentes fonctions. De plus, les études dé signalisation, dans différents organismes, ont placé TAK1, une MAP3K, à l'avant-plan dans l'activation des sentiers MAP kinase et des facteurs de transcription NF-kB. Nos efforts pour élucider les sentiers métaboliques du neutrophile nous ont fait nous pencher sur le rôle que TAK1 pouvait y jouer. Nous avons donc découvert que TAK1 était la kinase d'importance dans le contrôle des fonctions du neutrophile avec le LPS et le TNF[alpha], deux stimuli activateurs de NF-kB. Dans cette étude, nous nous sommes penchés sur le rôle de TAK1 chez le neutrophile avec des stimuli dont les réponses cellulaires ne passent pas par l'activation de NF-kB. C'est dans cette perspective que nous avons utilisé un chimioattractant, le fMLP, et un facteur de croissance, le GM-CSF. Ce sont deux stimuli physiologiques fréquemment retrouvés aux sites inflammatoires. Le fMLP et le GM-CSF activent rapidement TAK1 et celle-ci se retrouve en amont de la voie MEK/ERK, mais pas des voies p38 MAPK et PI3K/AKT. L'inhibition de TAK1 diminue l'expression et la sécrétion d'IL-8 et d'IL-1RA. L'inhibition de MEK/ERK et de PI3K/AKT a le même effet. De plus, l'inhibition de TAK1 empêche l'effet antiapoptotique du GM-CSF ainsi que diminue la production de leucotriènes par le fMLP. En conclusion, les travaux présentés montrent que TAK1 est une MAP3K essentielle dans les réponses fonctionnelles du neutrophile au fMLP et au GM-CSF. Cette découverte ouvre la porte à de nouvelles cibles thérapeutiques, particulièrement dans le cas de maladies chroniques impliquant le GM-CSF.

Macrophages serve key roles in host defence by initiating inflammatory responses to infection and/or injury. They contribute to innate immunity by secreting a range of pro-inflammatory cytokines (e.g. TNF and IL-6) upon activation as well as by phagocytosing pathogens and dead cells, which is necessary for the resolution of inflammation and effective wound repair. Macrophages also contribute to adaptive immunity by functioning as antigen presenting cells.Colony stimulating factor 1 (CSF-1) is the major growth factor governing the differentiation, proliferation and survival of macrophages. Although not as well appreciated, CSF-1 also regulates some of the immune functions of macrophages, such as cytokine secretion and phagocytosis. However, the mechanisms by which CSF-1 governs the immune functions of macrophages are poorly understood. Cytokine secretion, phagocytosis and antigen presentation involve various vesicle trafficking and membrane fusion events, processes in which SNARE proteins play vital roles. Thus, the hypothesis tested in this thesis was that CSF-1 modulates the immune functions of macrophages by regulating the expression and/or activity of SNARE proteins that regulate endocytic and exocytic processes.In this study, the endosomal SNARE protein syntaxin 7 was identified, via microarray analysis, as a CSF-1 inducible gene in primary mouse macrophages. Syntaxin 7 has previously been detected in phagosomal membranes in macrophages. Furthermore, syntaxin 7 has recently been implicated in the secretion of cytokines (e.g. TNF) from macrophages by forming a novel complex with syntaxin 6, Vti1b and VAMP3.

University, Diss., 2006--Giessen.

Zugl.: Giessen, Univ., Diss., 2006

Freiburg, Univ., Diss., 1999.

The colony-stimulating factor-1 receptor (CSF-1R) is expressed by the mononuclear phagocytic lineage, and is important for the development of these cells from their progenitors and also for promoting their survival and activation after maturation. The receptor has two ligands, CSF-1 and IL-34, which induce the formation of a stable dimer between two receptor monomers. This leads to intracellular autophosphorylation of tyrosine residues and subsequent signalling cascades, leading to rapid protein expression, cytoskeleton remodelling and cellular motility. Although CSF-1R signalling is crucial for normal embryogenic development and other physiological functions mediated by the phagocytic lineage, it has also been found to promote the pathogenic progression of cancer. Tumour-associated macrophages (TAMs) can comprise a large proportion of the cellular population in several solid tumours. These cells promote several hallmarks of cancer malignancy, such as increased neovascularization, tissue invasion, induction of metastases and immunosuppression. In this work, it was confirmed that CSF-1 had a prominent role in inducing cancer-promoting cellular phenotypes. Both canine cancer cells and macrophages respond to this cytokine, respectively increasing cancer cell proliferation and reducing inflammatory activation. Given the importance of CSF-1R signalling in the tumour microenvironment, antibodies were generated with the objective of blocking receptor function. Mice were immunized with either the extracellular region or the dimerization domain of the CSF-1R. Hybridomas were produced using the primed splenocytes, and monoclonal antibody (mAb) candidates were selected based on their performance in immunostaining and on their capacity to inhibit CSF-1R+ cells. The best antibodies were subjected to speciation. Chimeric antibodies maintained the ability of the parental mAbs to inhibit macrophage proliferation following CSF-1R stimulation. However, the mAbs possessed moderate affinity and specificity for their target, failing to stain monocytes and presenting a degree of cross-reactivity. The binding properties of one of such mAbs were altered by PCR-induced mutations, generating semi-synthetic antibody libraries. These were screened by phage display, yielding novel clones that show reduced cross-reactivity with unrelated proteins and retain the property of inhibiting macrophage survival. These results are a step in the development of therapeutic monoclonal antibodies for cancer treatment in dogs.

O sistema de expressão em Escherichia coli foi o primeiro a ser utilizado para produzir produtos farmacêuticos recombinantes e tem muitas vantagens quando comparado com sistemas eucarióticos, como o fácil cultivo, baixo custo e alto potencial de produção. O fator estimulador de colônias de granulócito (G-CSF) atua principalmente promovendo a maturação dos neutrófilos e estimulando sua atividade fagocítica e quimiotática, além de estar envolvido com o processo de segmentação nuclear dessas células. O fator estimulador de colônias de granulócitos humano recombinante (rhG-CSF) tem sido produzido por engenharia genética em Escherichia coli, e é usado no tratamento de diversas patologias, sobretudo em neutropenias provocadas pela quimioterapia usada no tratamento de tumores, pela radioterapia e pelo uso de drogas que suprimem a produção de células mieloides. Desse modo, o presente estudo teve como objetivo a expressão da proteína rhGCSF em bactérias Escherichia coli. A clonagem do gene rhG-CSF no vetor de expressão pET-28a(+) foi realizada nos sítios de restrição das enzimas EcoRI e XhoI, e a expressão da proteína recombinante em cepas de bactéria Escherichia coli BL21DE3 foi obtida com sucesso. A proteína rhG-CSF, fundida à cauda de seis histidinas, foi purificada com êxito e identificada pelas técnicas de Western Blotting e por espectrometria de massas. São necessários estudos para avaliar a integridade estrutural e atividade biológica da proteína produzida, que se confirmada, possibilita que esta seja produzida em escala piloto. / The expression system in Escherichia coli was the first to be used to produce recombinant pharmaceuticals and has many advantages compared to eukaryotic systems, such as easy cultivation and high production potential at low costs. The granulocyte colony (G-CSF) stimulating factor acts primarily by promoting the maturation of neutrophils and stimulating their phagocytic and chemotactic activity. G-CSF is also involved with the process of neutrophils nuclear segmentation. The recombinant human granulocyte colonies stimulating factor (rhG-CSF) has been produced by genetic engineering in Escherichia coli, and it is used to treat of several conditions, especially neutropenia caused by chemotherapy used in the treatment of tumors, by radiotherapy and by the use of drugs that suppress the production of myeloid cells. The present study aimed the expression of rhG-CSF protein in Escherichia coli bacteria. The cloning of rhG-CSF gene in the expression vector pET- 28a (+) was carried out on the restriction sites of the EcoRI and XhoI enzymes. Expression of the recombinant protein in Escherichia coli BL21DE3 was successfully achieved. The rhG-CSF protein, fused with a six histidine tag, was obtained and successfully purified and identified by the Western Blotting and by mass spectrometry techniques. Studies are needed to assess the structural integrity and biological activity of the protein produced, which, if confirmed, enables the production on a pilot scale.